Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

January 22, 2020

Study Completion Date

January 31, 2020

Conditions

Renal ImpairmentHealthy Participants

Interventions

DRUG

Linzagolix

A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions

Trial Locations (2)

Clinical Site, Orlando

Clinical Site, Saint Paul